Abstract
Body dysmorphic disorder is a challenging disorder that manifests as erroneously perceived flaws in one’s physical appearance and repetitive behaviors in response to appearance concerns. This disorder is also frequently comorbid with other psychiatric disorders, including major depressive disorder and autism spectrum disorder. It is currently understood to arise from a combination of biological, psychological, and environmental factors. Treatment of body dysmorphic disorder typically consists of a combination of pharmacotherapy and cognitive behavioral therapy. However, not all patients respond to treatment, and BDD symptoms remain even in those who do respond. This review outlines current pharmacological and neuromodulation treatments for body dysmorphic disorder and suggests directions for future studies of novel treatments such as augmentation with atypical antipsychotics and the use of intranasal oxytocin in cases of body dysmorphic disorder that show residual symptomatology even with tailored monotherapy. There is emerging evidence suggesting that non-invasive neurostimulatory techniques, such as repetitive transcranial magnetic stimulation, may be of value in treatment-resistant cases.
Keywords: Body dysmorphic disorder, antidepressants, TMS, fluoxetine, obsessive compulsive-related disorder, OCRD, SSRI.
Graphical Abstract
[1]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition (DSM-5); 5th ed.; American
Psychiatric Association: Arlington, VA, 2013.
[2]
Phillips, K.A. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder (Revised and Expanded Edition); New York: Oxford University Press, 2005.
[3]
Phillips, K.A. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull. Menninger Clin., 1998, 62(4)(Suppl. A), A33-A48. [PMID: 9810776].
[4]
Fang, A.; Wilhelm, S. Clinical features, cognitive biases, and treatment of body dysmorphic disorder. Annu. Rev. Clin. Psychol., 2015, 11, 187-212. [http://dx.doi.org/10.1146/annurev-clinpsy-032814-112849]. [PMID: 25581240].
[5]
Kaplan, R.A.; Rossell, S.L.; Enticott, P.G.; Castle, D.J. Own-body perception in body dysmorphic disorder. Cogn. Neuropsychiatry, 2013, 18(6), 594-614. [http://dx.doi.org/10.1080/13546805.2012. 758878]. [PMID: 23441837].
[6]
Phillipou, A.; Castle, D. Body dysmorphic disorder in men. Aust. Fam. Phys., 2015, 44(11), 798-801. [PMID: 26590618].
[7]
Weingarden, H.; Renshaw, K.D. Shame in the obsessive compulsive related disorders: a conceptual review. J. Affect. Disord., 2015, 171, 74-84. [http://dx.doi.org/10.1016/j.jad.2014.09.010]. [PMID: 25299438].
[8]
Kelly, M.M.; Didie, E.R.; Phillips, K.A. Personal and appearance-based rejection sensitivity in body dysmorphic disorder. Body Image, 2014, 11(3), 260-265. [http://dx.doi.org/10.1016/j.bodyim. 2014.03.004]. [PMID: 24958661].
[9]
Phillips, K.A.; Pinto, A.; Hart, A.S.; Coles, M.E.; Eisen, J.L.; Menard, W.; Rasmussen, S.A. A comparison of insight in body dysmorphic disorder and obsessive-compulsive disorder. J. Psychiatr. Res., 2012, 46(10), 1293-1299. [http://dx.doi.org/10.1016/j.jpsychires. 2012.05.016]. [PMID: 22819678].
[10]
Phillips, K.A.; Hart, A.S.; Simpson, H.B.; Stein, D.J. Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5. CNS Spectr., 2014, 19(1), 10-20. [http://dx.doi.org/10. 1017/S1092852913000266]. [PMID: 23659348].
[11]
Hartmann, A.S.; Thomas, J.J.; Wilson, A.C.; Wilhelm, S. Insight impairment in body image disorders: delusionality and overvalued ideas in anorexia nervosa versus body dysmorphic disorder. Psychiatry Res., 2013, 210(3), 1129-1135. [http://dx.doi.org/10.1016/j. psychres.2013.08.010]. [PMID: 23992792].
[12]
Phillips, K.A.; Kim, J.M.; Hudson, J.I. Body image disturbance in body dysmorphic disorder and eating disorders. Obsessions or delusions? Psychiatr. Clin. North Am., 1995, 18(2), 317-334. [PMID: 7659601].
[13]
Phillips, K.A.; Pinto, A.; Menard, W.; Eisen, J.L.; Mancebo, M.; Rasmussen, S.A. Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders. Depress. Anxiety, 2007, 24(6), 399-409. [http://dx.doi.org/ 10.1002/da.20232]. [PMID: 17041935].
[14]
Hollander, E.; Wong, C.M. Body dysmorphic disorder, pathological gambling, and sexual compulsions. J. Clin. Psychiatry, 1995, 56(Suppl. 4), 7-12. [PMID: 7713866].
[15]
Greenberg, J.L.; Mothi, S.S.; Wilhelm, S. Cognitive-behavioral therapy for body dysmorphic disorder by proxy. Behav. Ther., 2016, 47(4), 515-526. [http://dx.doi.org/10.1016/j.beth.2016.01.002]. [PMID: 27423167].
[16]
Angelakis, I.; Gooding, P.A.; Panagioti, M. Suicidality in body dysmorphic disorder (BDD): A systematic review with meta-analysis. Clin. Psychol. Rev., 2016, 49, 55-66. [http://dx.doi.org/ 10.1016/j.cpr.2016.08.002]. [PMID: 27607741].
[17]
Phillips, K.A.; Coles, M.E.; Menard, W.; Yen, S.; Fay, C.; Weisberg, R.B. Suicidal ideation and suicide attempts in body dysmorphic disorder. J. Clin. Psychiatry, 2005, 66(6), 717-725. [http://dx. doi.org/10.4088/JCP.v66n0607]. [PMID: 15960564].
[18]
Marques, L.; Weingarden, H.M.; Leblanc, N.J.; Wilhelm, S. Treatment utilization and barriers to treatment engagement among people with body dysmorphic symptoms. J. Psychosom. Res., 2011, 70(3), 286-293. [http://dx.doi.org/10.1016/j.jpsychores.2010.10. 002]. [PMID: 21334500].
[19]
IsHak. W.W.; Bolton, M.A.; Bensoussan, J.C.; Dous, G.V.; Nguyen, T.T.; Powell-Hicks, A.L.; Gardner, J.E.; Ponton, K.M. Quality of life in body dysmorphic disorder. CNS Spectr., 2012, 17(4), 167-175. [http://dx.doi.org/10.1017/S1092852912000624]. [PMID: 22939280].
[20]
Weingarden, H.; Renshaw, K.D.; Wilhelm, S.; Tangney, J.P.; DiMauro, J. Anxiety and shame as risk factors for depression, suicidality, and functional impairment in body dysmorphic disorder and obsessive compulsive disorder. J. Nerv. Ment. Dis., 2016, 204(11), 832-839. [http://dx.doi.org/10.1097/NMD.0000000000000498]. [PMID: 26998694].
[21]
Gunstad, J.; Phillips, K.A.; Axis, I. Axis I comorbidity in body dysmorphic disorder. Compr. Psychiatry, 2003, 44(4), 270-276. [http://dx.doi.org/10.1016/S0010-440X(03)00088-9]. [PMID: 12923704].
[22]
Mufaddel, A.; Osman, O.T.; Almugaddam, F.; Jafferany, M. A review of body dysmorphic disorder and its presentation in different clinical settings. Prim. Care Companion CNS Disord., 2013, 15(4), 15. [PMID: 24392251].
[23]
Vasudeva, S.B.; Hollander, E. Body dysmorphic disorder in patients with autism spectrum disorder: A reflection of increased local processing and self-focus. Am. J. Psychiatry, 2017, 174(4), 313-316. [http://dx.doi.org/10.1176/appi.ajp.2016.16050559]. [PMID: 28366095].
[24]
Veale, D.; Akyüz, E.U.; Hodsoll, J. Prevalence of body dysmorphic disorder on a psychiatric inpatient ward and the value of a screening question. Psychiatry Res., 2015, 230(2), 383-386. [http://dx. doi.org/10.1016/j.psychres.2015.09.023]. [PMID: 26404769].
[25]
Bohne, A.; Wilhelm, S.; Keuthen, N.J.; Florin, I.; Baer, L.; Jenike, M.A. Prevalence of body dysmorphic disorder in a German college student sample. Psychiatry Res., 2002, 109(1), 101-104. [http://dx. doi.org/10.1016/S0165-1781(01)00363-8]. [PMID: 11850057].
[26]
Veale, D.; Gledhill, L.J.; Christodoulou, P.; Hodsoll, J. Body dysmorphic disorder in different settings: A systematic review and estimated weighted prevalence. Body Image, 2016, 18, 168-186. [http://dx.doi.org/10.1016/j.bodyim.2016.07.003]. [PMID: 27498379].
[27]
Koran, L.M.; Abujaoude, E.; Large, M.D.; Serpe, R.T. The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr., 2008, 13(4), 316-322. [http://dx.doi.org/10. 1017/S1092852900016436]. [PMID: 18408651].
[28]
Bjornsson, A.S.; Didie, E.R.; Grant, J.E.; Menard, W.; Stalker, E.; Phillips, K.A. Age at onset and clinical correlates in body dysmorphic disorder. Compr. Psychiatry, 2013, 54(7), 893-903. [http://dx. doi.org/10.1016/j.comppsych.2013.03.019]. [PMID: 23643073].
[29]
Phillips, K.A.; Menard, W.; Quinn, E.; Didie, E.R.; Stout, R.L.A. A 4-year prospective observational follow-up study of course and predictors of course in body dysmorphic disorder. Psychol. Med., 2013, 43(5), 1109-1117. [http://dx.doi.org/10.1017/S003329171 2001730]. [PMID: 23171833].
[30]
Krebs, G.; Fernández de la Cruz, L.; Mataix-Cols, D. Recent advances in understanding and managing body dysmorphic disorder. Evid. Based Ment. Health, 2017, ebmental-2017-102702. [PMID: 28729345]
[31]
Buhlmann, U.; Marques, L.M.; Wilhelm, S. Traumatic experiences in individuals with body dysmorphic disorder. J. Nerv. Ment. Dis., 2012, 200(1), 95-98. [http://dx.doi.org/10.1097/NMD.0b013e31823 f6775]. [PMID: 22210370].
[32]
Buhlmann, U.; Cook, L.M.; Fama, J.M.; Wilhelm, S. Perceived teasing experiences in body dysmorphic disorder. Body Image, 2007, 4(4), 381-385. [http://dx.doi.org/10.1016/j.bodyim.2007.06. 004]. [PMID: 18089284].
[33]
Didie, E.R.; Tortolani, C.C.; Pope, C.G.; Menard, W.; Fay, C.; Phillips, K.A. Childhood abuse and neglect in body dysmorphic disorder. Child Abuse Negl., 2006, 30(10), 1105-1115. [http://dx. doi.org/10.1016/j.chiabu.2006.03.007]. [PMID: 17005251].
[34]
Grace, S.A.; Buchanan, B.G.; Maller, J.J.; Toh, W.L.; Castle, D.J.; Rossell, S.L. Reduced cortical thickness in body dysmorphic disorder. Psychiatry Res. Neuroimaging, 2017, 259, 25-28. [http://dx. doi.org/10.1016/j.pscychresns.2016.11.004]. [PMID: 27918913].
[35]
Grace, S.A.; Labuschagne, I.; Kaplan, R.A.; Rossell, S.L. The neurobiology of body dysmorphic disorder: A systematic review and theoretical model. Neurosci. Biobehav. Rev., 2017, 83, 83-96. [http://dx.doi.org/10.1016/j.neubiorev.2017.10.003]. [PMID: 29017915].
[36]
Feusner, J.D.; Townsend, J.; Bystritsky, A.; Bookheimer, S. Visual information processing of faces in body dysmorphic disorder. Arch. Gen. Psychiatry, 2007, 64(12), 1417-1425. [http://dx.doi.org/10. 1001/archpsyc.64.12.1417]. [PMID: 18056550].
[37]
Feusner, J.D.; Moody, T.; Hembacher, E.; Townsend, J.; McKinley, M.; Moller, H.; Bookheimer, S. Abnormalities of visual processing and frontostriatal systems in body dysmorphic disorder. Arch. Gen. Psychiatry, 2010, 67(2), 197-205. [http://dx.doi.org/10. 1001/archgenpsychiatry.2009.190]. [PMID: 20124119].
[38]
Feusner, J.D.; Hembacher, E.; Moller, H.; Moody, T.D. Abnormalities of object visual processing in body dysmorphic disorder. Psychol. Med., 2011, 41(11), 2385-2397. [http://dx.doi.org/10.1017/ S0033291711000572]. [PMID: 21557897].
[39]
Moody, T.D.; Sasaki, M.A.; Bohon, C.; Strober, M.A.; Bookheimer, S.Y.; Sheen, C.L.; Feusner, J.D. Functional connectivity for face processing in individuals with body dysmorphic disorder and anorexia nervosa. Psychol. Med., 2015, 45(16), 3491-3503. [http://dx.doi.org/10.1017/S0033291715001397]. [PMID: 26219399].
[40]
Vulink, N.C.; Planting, R.S.; Figee, M.; Booij, J.; Denys, D. Reduced striatal dopamine D2/3 receptor availability in Body Dysmorphic Disorder. Eur. Neuropsychopharmacol., 2016, 26(2), 350-356. [http://dx.doi.org/10.1016/j.euroneuro.2015.11.018]. [PMID: 26711686].
[41]
Tasios, K.; Michopoulos, I. Body dysmorphic disorder: Latest neuroanatomical and neuropsychological findings. Psychiatriki, 2017, 28(3), 242-250. [http://dx.doi.org/10.22365/jpsych.2017.283. 242]. [PMID: 29072188].
[42]
Grant, J.E.; Fineberg, N.; van Ameringen, M.; Cath, D.; Visser, H.; Carmi, L.; Pallanti, S.; Hollander, E.; van Balkom, A.J.L.M. New treatment models for compulsive disorders. Eur. Neuropsychopharmacol., 2016, 26(5), 877-884. [http://dx.doi.org/10.1016/j. euroneuro.2015.11.008]. [PMID: 26621260].
[43]
Phillips, K.A. Body Dysmorphic Disorder: Advances in Research and Clinical Practice; Oxford, New York: Oxford University Press , 2017. [http://dx.doi.org/10.1093/med/9780190254131.001.0001]
[44]
Frías, Á.; Palma, C.; Farriols, N.; González, L. Comorbidity between obsessive-compulsive disorder and body dysmorphic disorder: prevalence, explanatory theories, and clinical characterization. Neuropsychiatr. Dis. Treat., 2015, 11, 2233-2244. [http://dx.doi. org/10.2147/NDT.S67636]. [PMID: 26345330].
[45]
Phillips, K.A. Understanding Body Dysmorphic Disorder; Oxford, New York: Oxford University Press , 2009.
[46]
Phillips, K.A.; Albertini, R.S.; Siniscalchi, J.M.; Khan, A.; Robinson, M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J. Clin. Psychiatry, 2001, 62(9), 721-727. [http://dx.doi.org/10.4088/JCP.v62n0910]. [PMID: 11681769].
[47]
Phillips, K.A.; Albertini, R.S.; Rasmussen, S.A. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch. Gen. Psychiatry, 2002, 59(4), 381-388. [http://dx.doi.org/10. 1001/archpsyc.59.4.381]. [PMID: 11926939].
[48]
Phillips, K.A.; Kelly, M.M. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int. Clin. Psychopharmacol., 2009, 24(1), 26-28. [http://dx.doi.org/10.1097/YIC. 0b013e32831db2e9]. [PMID: 19060721].
[49]
Phillips, K.A. Pharmacotherapy for body dysmorphic disorder. Psychiatr. Ann., 2010, 40(7), 325-332. [http://dx.doi.org/10.3928/ 00485713-20100701-05]. [PMID: 27761054].
[50]
Phillips, K.A.; Hollander, E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image, 2008, 5(1), 13-27. [http://dx.doi.org/10.1016/ j.bodyim.2007.12.003]. [PMID: 18325859].
[51]
Phillips, K.A.; Keshaviah, A.; Dougherty, D.D.; Stout, R.L.; Menard, W.; Wilhelm, S. Pharmacotherapy relapse prevention in body dysmorphic disorder: A double-blind, placebo-controlled trial. Am. J. Psychiatry, 2016, 173(9), 887-895. [http://dx.doi.org/ 10.1176/appi.ajp.2016.15091243]. [PMID: 27056606].
[52]
Hollander, E.; Hong, K. Relapse prevention and the need for ongoing pharmacological treatment in body dysmorphic disorder. Am. J. Psychiatry, 2016, 173(9), 857-859. [http://dx.doi.org/10. 1176/appi.ajp.2016.16050624]. [PMID: 27581691].
[53]
Rashid, H.; Khan, A.A.; Fineberg, N.A. Adjunctive antipsychotic in the treatment of body dysmorphic disorder - A retrospective naturalistic case note study. Int. J. Psychiatry Clin. Pract., 2015, 19(2), 84-89. [http://dx.doi.org/10.3109/13651501.2014.981546]. [PMID: 25363200].
[54]
Marroni, S.S.; Nakano, F.N.; Gati, C.D.C.; Oliveira, J.A.; Antunes-Rodrigues, J.; Garcia-Cairasco, N. Neuroanatomical and cellular substrates of hypergrooming induced by microinjection of oxytocin in central nucleus of amygdala, an experimental model of compulsive behavior. Mol. Psychiatry, 2007, 12(12), 1103-1117. [http://dx.doi.org/10.1038/sj.mp.4002015]. [PMID: 17505467].
[55]
Kang, J.I.; Kim, H.W.; Kim, C.H.; Hwang, E.H.; Kim, S.J. Oxytocin receptor gene polymorphisms exert a modulating effect on the onset age in patients with obsessive-compulsive disorder. Psychoneuroendocrinology, 2017, 86, 45-52. [http://dx.doi.org/10.1016/ j.psyneuen.2017.09.011]. [PMID: 28915380].
[56]
Hollander, E. Social synchrony and oxytocin: from behavior to genes to therapeutics. Am. J. Psychiatry, 2013, 170(10), 1086-1089. [http://dx.doi.org/10.1176/appi.ajp.2013.13070848]. [PMID: 24084810].
[57]
Park, H.R.; Kim, I.H.; Kang, H.; Lee, D.S.; Kim, B-N.; Kim, D.G.; Paek, S.H. Nucleus accumbens deep brain stimulation for a patient with self-injurious behavior and autism spectrum disorder: functional and structural changes of the brain: report of a case and review of literature. Acta Neurochir. (Wien), 2017, 159(1), 137-143. [http://dx.doi.org/10.1007/s00701-016-3002-2]. [PMID: 27807672].
[58]
Mahato, R.S.; San, G.M.C.P.; Longshore, C.T.; Schnur, D.B. A case of treatment-resistant depression and body dysmorphic disorder: The role of electroconvulsive therapy revisited. Innov. Clin. Neurosci., 2016, 13(7-8), 37-40. [PMID: 27672487].
[59]
Kumar, S.; Singh, S.; Chadda, R.K.; Verma, R.; Kumar, N. The effect of low-frequency repetitive transcranial magnetic stimulation at orbitofrontal cortex in the treatment of patients with medication-refractory obsessive-compulsive disorder: A retrospective open study. J. ECT, 2017. [http://dx.doi.org/10.1097/YCT.0000000000000462]. [PMID: 29053484].
[60]
Carmi, L.; Alyagon, U.; Barnea-Ygael, N.; Zohar, J.; Dar, R.; Zangen, A. Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. Brain Stimul., 2018, 11(1), 158-165. [http://dx.doi.org/10. 1016/j.brs.2017.09.004]. [PMID: 28927961].
[61]
Haghighi, M.; Shayganfard, M.; Jahangard, L.; Ahmadpanah, M.; Bajoghli, H.; Pirdehghan, A.; Holsboer-Trachsler, E.; Brand, S. Repetitive Transcranial Magnetic Stimulation (rTMS) improves symptoms and reduces clinical illness in patients suffering from OCD--Results from a single-blind, randomized clinical trial with sham cross-over condition. J. Psychiatr. Res., 2015, 68, 238-244. [http://dx.doi.org/10.1016/j.jpsychires.2015.06.020]. [PMID: 26228425].
[62]
Ma, Z-R.; Shi, L-J. Repetitive transcranial magnetic stimulation (rTMS) augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD): a meta-analysis of randomized controlled trials. Int. J. Clin. Exp. Med., 2014, 7(12), 4897-4905. [PMID: 25663986].
Related Journals
Current Drug Safety
Current Pharmaceutical Design
Current Neurovascular Research
Current Pharmaceutical Analysis
Central Nervous System Agents in Medicinal Chemistry
Current Vascular Pharmacology
Current Alzheimer Research
CNS & Neurological Disorders - Drug Targets
Current Molecular Pharmacology
Current Aging Science
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Frontiers in Clinical Drug Research-Dementia
Article Metrics
39
2